Incretin based treatments and mortality in patients with type 2 diabetes: Systematic review and meta-analysis

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Liu, Jiali ^a   Li, Ling ^a   Deng, Ke ^a   Xu, Chang ^a   Busse, Jason W ^b,c   Vandvik, Per Olav ^d,e   Li, Sheyu ^a   Guyatt, Gordon H ^b   Sun, Xin ^a  

^a SICHUAN UNIVERSITY   (China)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^e INNLANDET HOSPITAL TRUST   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; OMARIGLIPTIN; PLACEBO; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; TASPOGLUTIDE; TENELIGLIPTIN; VILDAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ARTICLE; CONFIDENCE INTERVAL; DRUG EFFICACY; HUMAN; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGONISTS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHY;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85020624976     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2499     Document Type: Article

References (57)

1. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2016;18:203-16. doi:10.1111/dom.12591.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9. doi:10.2337/dc14-2441.
3. Tricco AC, Antony J, Khan PA, et al. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open 2014;4:e005752. doi:10.1136/bmjopen-2014-005752.
4. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369. doi:10.1136/bmj.e1369.
5. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258.e22. doi:10.1016/j.clinthera.2012.04.013.
6. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. J Hypertens 2016;34:167-75. doi:10.1097/HJH.0000000000000782.
7. Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2015;17:1065-74. doi:10.1111/dom.12541.
8. Sun F, Chai S, Li L, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res 2015;2015:157201. doi:10.1155/2015/157201.
9. Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin 2011;27:1519-28. doi:10.1185/03007995.2011.590127.
10. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014;27:130-9. doi:10.1093/ajh/hpt196.
11. Kawalec P, Mikrut A, Łopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014;30:269-83. doi:10.1002/dmrr.2494.
12. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. doi:10.1056/NEJMoa1307684.
13. Lisa Yanoff MD. Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm444144.pdf
14. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015;373:232-42. doi:10.1056/NEJMoa1501352.
15. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. doi:10.1056/NEJMoa1305889.
16. Mogensen UM, Andersson C, Fosbol EL, et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus-a retrospective nationwide study. Diabetes Obes Metab 2014;16:1001-8. doi:10.1111/dom.12314.
17. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all cause mortality. Diabetes Obes Metab 2014;16:977-83. doi:10.1111/dom.12306.
18. Velez M, Peterson EL, Wells K, et al. Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 2015;21:2-8. doi:10.1016/j.cardfail.2014.10.012.
19. Wang KL, Liu CJ, Chao TF, et al. Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol 2014;177:86-90. doi:10.1016/j.ijcard.2014.09.038.
20. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2014;2:573-82. doi:10.1016/j.jchf.2014.04.005.
21. Giorda CB, Picariello R, Tartaglino B, et al. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. BMJ Open 2015;5:e007959. doi:10.1136/bmjopen-2015-007959.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41. doi:10.1016/j.ijsu.2010.02.007.
23. ClinicalTrials.gov. Why should I register and submit results? http://www.clinicaltrials.gov/ct2/manage-recs/background
24. US Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. US Public Law 110-85 section 801. http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf
25. Akl EA, Sun X, Busse JW, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol 2012;65:262-7. doi:10.1016/j. jclinepi.2011.04.015.
26. Guyatt GH, Busse JW. Modification of Cochrane Tool to assess risk of bias in randomized trials. https://www.evidencepartners.com/resources/methodological-resources/
27. Higgins JP, Altman DG, Gotzsche PC, et al. Cochrane Bias Methods Group Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928.
28. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. 2011. http://handbook.cochrane.org/
29. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77. doi:10.1002/sim.2528.
30. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007;7:5. doi:10.1186/1471-2288-7-5.
31. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75. doi:10.1002/sim.1761.
32. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117. doi:10.1136/bmj.c117.
33. Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. doi:10.1136/bmj.39489.470347.AD.
34. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-22. doi:10.1056/NEJMoa1603827.
35. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-44. doi:10.1056/NEJMoa1607141.
36. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373:2247-57. doi:10.1056/NEJMoa1509225.
37. de Wit HM, Te Groen M, Rovers MM, Tack CJ. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;82:301-14. doi:10.1111/bcp.12925.
38. Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract 2014;68:557-67. doi:10.1111/ijcp.12361.
39. Boland CL, Degeeter M, Nuzum DS, Tzefos M. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Ann Pharmacother 2013;47:490-505. doi:10.1345/aph.1R444.
40. Zang L, Liu Y, Geng J, et al. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Diabetes Obes Metab 2016;18:803-11. doi:10.1111/dom.12674.
41. Van Gaal L, Souhami E, Zhou T, Aronson R. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus. J Clin Transl Endocrinol 2014;1:31-7doi:10.1016/j.jcte.2014.03.001.
42. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252-8. doi:10.2337/dc11-1107.
43. Pratley R, Nauck M, Bailey T, et al. 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407. doi:10.1111/j.1742-1241.2011. 02656.x.
44. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-58. doi:10.2337/dc13-2761.
45. Charbonnel B, Steinberg H, Eymard E, et al. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 2013;56:1503-11. doi:10.1007/s00125-013-2905-1.
46. Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther 2012;3:13. doi:10.1007/s13300-012-0013-8.
47. Bailey TS, Takács R, Tinahones FJ, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, doubledummy, active-controlled 26-week trial. Diabetes Obes Metab 2016;18:1191-8. doi:10.1111/dom.12736.
48. Eli Lilly and Company. United BioSource CorporationTessella Inc. Berry Consultants. A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin. National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT00734474
49. GlaxoSmithKline. A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT01098539
50. GlaxoSmithKline. Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes. National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/NCT00838903
51. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764. doi:10.1155/2011/215764.
52. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:38-47. doi:10.1111/dom.12175.
53. Ding S, Du YP, Lin N, et al. Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Int J Cardiol 2016;222:957-62. doi:10.1016/j.ijcard.2016.07.199.
54. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35. doi:10.1016/j.numecd.2009.03.015.
55. Savarese G, Perrone-Filardi P, D'Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. Int J Cardiol 2015;181:239-44. doi:10.1016/j. ijcard.2014.12.017.
56. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014;32:147-58. doi:10.1111/1755-5922.12075.
57. Savarese G, D'Amore C, Federici M, et al. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. Int J Cardiol 2016;220:595-601. doi:10.1016/j.ijcard.2016.06.208.